Phone (Mobile)
+1 973 ❅❅❅ ❅❅❅❅
Phone (Mobile)
Phone (HQ)
(617) 941-7468
Phone (HQ)
❅❅❅❅❅@avencell.com
❅❅❅❅❅@yahoo.com
Office Address (HQ)
51 Moulton St, Cambridge, Massachusetts, 02138, United States
Office Address (HQ)
Get 10 Free Leads on us
Use our Chrome Extension & instantly connect with prospects
Andrea Kistner
Avencell Therapeutics
Get Free Access to Andrea’s Contact InfoAccording to Datanyze information, these are Andrea Kistner's contact details. Reveal the hidden information below for FREE!
Phone (Mobile)
+1 973 ❅❅❅ ❅❅❅❅
Phone (Mobile)
Phone (HQ)
(617) 941-7468
Phone (HQ)
❅❅❅❅❅@avencell.com
❅❅❅❅❅@yahoo.com
Office Address (HQ)
51 Moulton St, Cambridge, Massachusetts, 02138, United States
Office Address (HQ)
Andrea Kistner works as a Vice President, Finance & Corporate Controller at Avencell Therapeutics, which is a Chemicals & Related Products company with an estimated 33 employees; and founded in 2021. They are part of the Accounting team within the Finance Department and their management level is VP-Level. Andrea graduated from Post University and is currently based in Cambridge, United States. They used to work at Castle Creek Biosciences and Recordati Rare Diseases and have used the following emails: @avencell.com, @roxiticusventures.com, @castlecreekpharma.com.
Pro tip before reaching out: Read up on Cambridge’s current events to ❄️
Andrea Kistner's career began less then a year ago. Prior to joining Avencell Therapeutics, Andrea worked at 7 companies.
Vice President, Finance
Senior Director, Accounting
Director, Finance & Regional Chief Financial Officer, Administration
Vice President, Finance
Controller
Partner
Manager, Licensing
Bachelor of Science
Post University
Avencell Therapeutics
51 Moulton St, Cambridge, Massachusetts, 02138, United States
33
$7.8 M
Chemicals & Related Products, Manufacturing, Business Services, Research & Development
Get Full Profile Access
Ice Breakers
Imagine you could know all about Avencell Therapeutics - Andrea Kistner’s company, before you contact them. Warm up a cold prospect with Datanyze icebreakers
Andrea’s company in the news
AvenCell Announces First Patient Dosed in a Phase IA Study with lead product candidate AVC-201, a Novel Allogeneic CD123-Directed Switchable CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and other CD123 Hematological Malignancies
February 6, 2024
Insights to Break the Ice
In your first interaction
Andrea’s CEO is Deborah Grey
Andrea is located in United States
Work Colleague
See Andrea Kistner's coworkers out of Avencell Therapeutics's 33 employees